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Derivation and isolation of mouse mesenchymal stem cells from induced pluripotent stem cells
YY Chow, QZ Lian, HF Tse
Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong
introduction: Transplantation of adult donors’–derived mesenchymal stem cells (MSCs) is able to improve cardiac 
function in experimental acute myocardial infarction models. However, the poor survival rate of adult MSCs in 
ischaemic environment has limited its therapeutic efficiency. Previous investigations have indicated that MSCs derived 
from early embryonic stage such as embryonic stem cells or induced pluripotent stem cells (iPSCs) have greater 
potential of proliferation and differentiation. Nevertheless, up to date, therapeutic capacity of mouse MSCs derived 
from iPSCs remains elusive. This ongoing study therefore aimed to derive and isolate mouse MSCs from iPSCs for 
attenuation of tissue ischaemia. We hypothesise that transplantation of mouse-induced pluripotent stem cell–derived 
mesenchymal stem cells (iPSC-MSCs) will achieve a better therapeutic efficiency by enhanced retention or survival rate 
compared to adult bone marrow–derived mesenchymal stem cells. 
Methods: We utilised a three stepwise method to derive and isolate mesenchymal-like stem cells from mouse 
iPSCs. Firstly, feeder cells and leukaemia inhibitory factor (LIF) were removed to induce iPSCs into spontaneous 
differentiation. The subsequent step is enrichment of MSCs by conditioned medium with basic fibroblast growth 
factor (FGF2) and epidermal growth factor (EGF) supplements. Lastly, isolation of enriched MSCs was analysed by 
fluorescence-activated cell sorting (FACS) to isolate subpopulation CD90+/CD133-. The single cell–derived MSC-liked 
colonies were expanded by limiting dilution. These cells were subjected to surface markers profiling and multipotent 
differentiation studies, namely adipogenesis, osteogenesis and chondrogenesis.
Results: The iPSC-derived cells were morphologically similar to adult bone marrow–derived MSCs. These cells were 
negative for CD34, anti Oct4, anti TRA-1-60 and CD133, while being positive for mesenchymal markers, CD44, 
CD73 and CD90. These cells were further induced into adipocytes, osteocytes and chondrocytes under differentiation-
conditioned medium. 
Conclusion: Derivation of mouse mesenchymal stem cells from mouse-induced pluripotent stem cells was successful. 
These cells hold potential therapeutic properties for ischaemic disease regeneration in near future.
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Enhanced therapeutic efficacy of transarterial chemoembolisation treatment in hepatocelluar  
carcinoma (HCC) by mTOR inhibitor RAD001: implication for a novel treatment regimen in HCC
ACY Chu1, RTP Poon1,2, SC Lam1,3, KM Chow1, R Pang1,3
1Centre for Cancer Research, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong
2Department of Surgery, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong 
3Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong
introduction: Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. Transarterial 
chemoembolisation (TACE) is commonly used for the treatment of locally advanced HCC by dual actions of 
chemotherapy and ischaemic hypoxia. In this study, the therapeutic efficacy of RAD001, a novel mTOR inhibitor and 
its potential combinatory use with TACE for treatment of HCC using orthotropic HCC models was investigated. 
Methods: Therapeutic efficacy of RAD001 and TACE was investigated in vivo and in vitro. For in-vivo studies, equal 
portions of established xenografts were orthotopically implanted into mice to generate HCC tumours. RAD001 was 
administered orally or by intraportal vein injection, hepatic artery ligation was performed to mimic transarterial 
chemoembolisation treatment, and chemotherapeutic effect was achieved by intraportal injection of cisplatin. For in-
vitro studies, MHCC97L cells were treated with cisplatin and RAD001 under normoxic and hypoxic conditions to 
investigate their biological effects on HCC cells, including cell proliferation and regulation of different targets in mTOR 
pathway. 
Results: Significant inhibition of tumour growth was observed when MHCC97L was treated with RAD001 and 
cisplatin in orthotopic mouse models. Combination of hepatic artery ligation combined with RAD001 treated 
through portal vein led to >90% tumour shrinkage when compared with the non-treated HCC controls. In addition, 
synergetic inhibitory effect was observed when RAD001 combined with cisplatin treated through TACE in orthotropic 
HCC model. In-vitro studies also showed inhibition of cell proliferation by 52% and 40% in normoxic and hypoxic 
condition, respectively, when treated with 10 nm RAD001 alone. Cell proliferation was further inhibited when treated 
in combination with 2 mg/mL of cisplatin by 56% under normoxia and 36% by hypoxia. Western blot analysis 
revealed inhibition of mTOR, p70S6K(thr389) and PRAS40 phosphorylation by RAD001, and also downregulation of 
HIF-1α via the mTOR pathway under hypoxic conditions. 
Conclusion: RAD001 used in combination with TACE could effectively inhibit tumour growth via the mTOR pathway 
and also enhances the cisplatin-induced toxicity towards HCC, providing the basis for use of RAD001 in combination 
with TACE + cisplatin as an effective regimen for treatment of HCC.
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